Dizal Pharmaceutical(SH:688192) Xin Lang Cai Jing·2025-12-25 01:38Core Viewpoint - Dize Pharmaceutical has shown a mixed financial performance with significant revenue growth but a net loss, indicating potential challenges in profitability despite strong sales growth [2] Group 1: Stock Performance - On December 24, Dize Pharmaceutical's stock increased by 0.10% with a trading volume of 64.13 million yuan [1] - The financing buy-in amount on the same day was 4.90 million yuan, while the financing repayment was 2.80 million yuan, resulting in a net financing buy of 2.11 million yuan [1] - As of December 24, the total margin trading balance for Dize Pharmaceutical was 184 million yuan, with a financing balance of 183 million yuan, accounting for 0.67% of the circulating market value [1] Group 2: Financial Performance - For the period from January to September 2025, Dize Pharmaceutical achieved a revenue of 586 million yuan, representing a year-on-year growth of 73.23% [2] - The net profit attributable to the parent company was -580 million yuan, reflecting a year-on-year decrease of 3.85% [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Dize Pharmaceutical was 8,806, an increase of 5.01% compared to the previous period [2] - The average number of circulating shares per shareholder was 46,528, which is an increase of 108.97% from the previous period [2] - Notable changes in institutional holdings include Yongying Pharmaceutical Innovation Mixed Fund becoming the fourth largest shareholder with 5.91 million shares, an increase of 2.30 million shares [2]